Skip to main content

What CytoAgents' new $2M grant from NIH will help the biotech firm do

The company's drug candidate treats a deadly complication of Covid-19 and other respiratory illnesses.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.